Transductional and Transcriptional Targeting of Adenovirus for Clinical Applications
J. N. Glasgow, G. J. Bauerschmitz, D. T. Curiel and A. Hemminki
Affiliation: Rational Drug Design Program Department of Oncology, Biomedicum, P.O. Box 63, 00014University of Helsinki, Finland (street address: Haartmaninkatu 8, 00290 Helsinki).
Adenovirus (Ad) targeting is a novel approach for the design and administration of therapeutic agents wherein the agent is rationally designed to localize and restrict transgene expression to the site of disease in a self-directed manner, usually via exploitation of unique biophysical and genetic properties specific to the diseased tissue. The ablation of promiscuous native Ad tropism coupled with active targeting modalities has demonstrated that innate gene delivery efficiency may be retained while circumventing Ad dependence on its primary cellular receptor, the coxsackie and adenovirus receptor (CAR), to achieve CAR-independent vector tropism. Herein, we describe advances in Ad targeting that are predicated not only on fundamental understanding of vector / cell interplay, but also on the specific transcriptional profiles of target tissues. Further, targeting is discussed in the context of improving the safety and efficacy of clinical approaches utilizing adenoviral vectors and replication competent oncolytic agents. In summary, existing results suggest a critical linkage between targeted agents and increases in therapeutic utility.
Keywords: review, vector targeting, gene therapy, adenovirus
Rights & PermissionsPrintExport